Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,733 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: EXTEND Plus Clear all
Terminated Phase 3 Interventional Results available

Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial

NCT04049097
View directory record Official record
Conditions
Inclusion Body Myositis
Interventions
Arimoclomol
Drug
Lead sponsor
ZevraDenmark
Industry
Eligibility
45 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
11
States / cities
Phoenix, Arizona • Irvine, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Sep 2, 2026, 4:40 AM EDT
Completed Not applicable Interventional

Conservative Treatment of Mallet Finger Injury

NCT04830917
View directory record Official record
Conditions
Conservatively Treated Mallet Finger Injury
Interventions
Immobilization type for mallet injury
Other
Lead sponsor
Orthopaedic Specialty Group PC, Fairfield
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Fairfield, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Sep 2, 2026, 4:40 AM EDT
Not listed Not applicable Interventional

Korean Medicine for Symptomatic Lumbar Spinal Spondylolisthesis

NCT03107468
View directory record Official record
Conditions
Spondylolisthesis, Lumbosacral Region
Interventions
Mokhuri intensive treatment, Non-surgical conventional standard treatment
Other
Lead sponsor
Kim Ki Ok
Other
Eligibility
19 Years to 78 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 2, 2026, 4:40 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

NCT04770779
View directory record Official record
Conditions
Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia
Interventions
Placebo Matching Mitapivat, Mitapivat
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
10
States / cities
Phoenix, Arizona • La Jolla, California • Oakland, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 2, 2026, 4:40 AM EDT
Completed Phase 2 Interventional

A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

NCT06046443
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
LB54640, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Aurora, Colorado • Iowa City, Iowa • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 2, 2026, 4:40 AM EDT
Terminated Not applicable Interventional Results available

Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)

NCT00870818
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Blood samples for safety, Patient reported outcome questionnaires, Analysis of T-cell subsets
Diagnostic Test · Behavioral
Lead sponsor
MacroGenics
Industry
Eligibility
10 Years to 37 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Sep 2, 2026, 4:40 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773

NCT01395810
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia B
Interventions
nonacog beta pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
13 Years to 70 Years · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Sep 2, 2026, 4:40 AM EDT
Completed Phase 1Phase 2 Interventional

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT04815720
View directory record Official record
Conditions
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Interventions
pepinemab + pembrolizumab
Drug
Lead sponsor
Vaccinex Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
15
States / cities
Springdale, Arkansas • Fresno, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 2, 2026, 4:40 AM EDT
Terminated Phase 3 Interventional Results available

Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy

NCT00108485
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Kidney Failure, Chronic, Hyperlipidemia
Interventions
Extended release niacin, Placebo
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Sep 2, 2026, 4:40 AM EDT
Completed Not applicable Interventional

Oral Health Intervention Pilot Study for Individuals With Memory Problems

NCT01808235
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Oral Health Intervention
Behavioral
Lead sponsor
Duke University
Other
Eligibility
60 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Sep 2, 2026, 4:40 AM EDT
Completed No phase listed Observational

Artificial Intelligence for Digital Cholangioscopy Neoplasia Diagnosis

NCT05147389
View directory record Official record
Conditions
Common Bile Duct Neoplasms, Non-Neoplastic Bile Duct Disorder
Interventions
AI model classification, DSOC endoscopist experts' classification
Diagnostic Test
Lead sponsor
Instituto Ecuatoriano de Enfermedades Digestivas
Other
Eligibility
18 Years to 79 Years
Enrollment
170 participants
Timeline
2020 – 2022
U.S. locations
3
States / cities
New Brunswick, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Sep 2, 2026, 4:40 AM EDT
Completed Phase 2 Interventional Results available

Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma

NCT02484443
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Recurrent Osteosarcoma
Interventions
Dinutuximab, Laboratory Biomarker Analysis, Pharmacological Study, Sargramostim
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 29 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
111
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 91 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 2, 2026, 4:40 AM EDT
Enrolling by invitation Phase 2 Interventional

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

NCT05669989
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone, Lenalidomide, Pomalidomide, Isatuximab subcutaneous (SC), Carfilzomib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 2, 2026, 4:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Start the Conversation: Evaluating Implementation of a Multi-level PrEP Initiative for Black Cisgender Women in Nola

NCT05909176
View directory record Official record
Conditions
Preexposure Prophylaxis, HIV Infections
Interventions
GYN Residency Training, Social Media Campaign
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 99 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 2, 2026, 4:40 AM EDT
Withdrawn Phase 2 Interventional

Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients

NCT02678520
View directory record Official record
Conditions
Prostate Cancer
Interventions
3-D Conformal Radiation Therapy, Intensity Modulated Radiation Therapy, Casodex, Zoladex , Lupron
Radiation · Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fairway, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Sep 2, 2026, 4:40 AM EDT
Active, not recruiting Phase 3 Interventional

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

NCT06869785
View directory record Official record
Conditions
Relapsing Multiple Sclerosis (RMS)
Interventions
Ofatumumab approved dose, Ofatumumab new dose
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 2, 2026, 4:40 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

NCT04281108
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Drug · Procedure
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Anniston, Alabama • Dothan, Alabama • Mobile, Alabama + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Sep 2, 2026, 4:40 AM EDT
Completed Early Phase 1 Interventional Results available

A Microdose Evaluation Study of ABY-029 in Recurrent Glioma

NCT02901925
View directory record Official record
Conditions
Glioma
Interventions
ABY-029
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 2, 2026, 4:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients

NCT02743897
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Zepatier, Mavyret
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 2, 2026, 4:40 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Telemonitoring Versus Usual Care

NCT01056640
View directory record Official record
Conditions
Health Care Quality, Health Care Access
Interventions
Intel Health Guide, Usual Care
Device · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years and older
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Sep 2, 2026, 4:40 AM EDT
Completed Phase 2Phase 3 Interventional

EXHIT ENTRE Comparative Effectiveness Trial

NCT04345718
View directory record Official record
Conditions
Substance Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Interventions
Extended Release Buprenorphine, Treatment as Usual
Drug
Lead sponsor
Gavin Bart
Other
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 2, 2026, 4:40 AM EDT
Completed Not applicable Interventional

Helping Individuals With Firearm Injuries

NCT02630225
View directory record Official record
Conditions
Wounds, Gunshot
Interventions
Critical Time Intervention, Treatment as Usual, Motivational Interviewing, Multi-Agency Attention
Behavioral · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 5, 2020 · Synced Sep 2, 2026, 4:40 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Gabapentin in Postherpetic Neuralgia

NCT00335933
View directory record Official record
Conditions
Neuralgia, Postherpetic
Interventions
Gabapentin extended-release tablets
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2007 · Synced Sep 2, 2026, 4:40 AM EDT
Not listed No phase listed Observational

Assessing Breast Density's Value in Imaging - A Comparative Effectiveness Study

NCT02980848
View directory record Official record
Conditions
Breast Cancer
Interventions
Screening digital mammography, Screening digital breast tomosynthesis, Screening breast magnetic resonance imaging, Diagnostic mammography, Pre-operative breast magnetic resonance imaging
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
1,341,172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
7
States / cities
Davis, California • San Francisco, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Sep 2, 2026, 4:40 AM EDT